Matches in Wikidata for { <http://www.wikidata.org/entity/Q61907881> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q61907881 description "assaig clínic" @default.
- Q61907881 description "clinical trial" @default.
- Q61907881 description "clinical trial" @default.
- Q61907881 description "clinical trial" @default.
- Q61907881 description "clinical trial" @default.
- Q61907881 description "ensaio clínico" @default.
- Q61907881 description "ensayo clínico" @default.
- Q61907881 description "ensayu clínicu" @default.
- Q61907881 description "essai clinique" @default.
- Q61907881 description "klinisch onderzoek" @default.
- Q61907881 description "клінічне випробування" @default.
- Q61907881 name "Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)" @default.
- Q61907881 type Item @default.
- Q61907881 label "Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)" @default.
- Q61907881 prefLabel "Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)" @default.
- Q61907881 P1050 Q61907881-F68D5CC9-332B-45F1-AAB8-9EE5A2001FB4 @default.
- Q61907881 P1132 Q61907881-BE29100F-A240-4C61-B659-CE050574828F @default.
- Q61907881 P1476 Q61907881-37A13494-30F3-4CC5-8DDF-A4201C2ABD95 @default.
- Q61907881 P17 Q61907881-362B4F6F-1655-4A48-B7AB-8B2E3B1A4260 @default.
- Q61907881 P17 Q61907881-82EA892A-35C6-4365-8064-917300A2973A @default.
- Q61907881 P17 Q61907881-DB6108FB-628B-4330-9EB8-4133DF73B4ED @default.
- Q61907881 P2899 Q61907881-20BD9F2F-A949-458A-9BD2-C0FB5A4BE312 @default.
- Q61907881 P3098 Q61907881-10FF757B-1D93-4B6F-942D-70884980BA12 @default.
- Q61907881 P31 Q61907881-2E17CD55-B0CC-49A8-BF83-C4E0F6197D2F @default.
- Q61907881 P4844 Q61907881-89D800D8-EC23-4626-81A2-F27E8DAE3E15 @default.
- Q61907881 P580 Q61907881-F11971BF-A502-462B-832F-3E05E13C4858 @default.
- Q61907881 P582 Q61907881-82A287F1-B12F-4469-80BE-661CF578AEAA @default.
- Q61907881 P6099 Q61907881-B196C1B7-A974-49A1-89F8-AE13F7924F96 @default.
- Q61907881 P6099 Q61907881-DCF9CF74-26C5-48B0-AC95-81BFC0341E67 @default.
- Q61907881 P8363 Q61907881-1F802241-6E4A-4895-B59D-3B07C57B8ED3 @default.
- Q61907881 P859 Q61907881-D075F0A3-5F9C-41BD-B78D-9CF2C62E8D7E @default.
- Q61907881 P1050 Q208414 @default.
- Q61907881 P1132 "+134" @default.
- Q61907881 P1476 "A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies" @default.
- Q61907881 P17 Q30 @default.
- Q61907881 P17 Q408 @default.
- Q61907881 P17 Q801 @default.
- Q61907881 P2899 "+18" @default.
- Q61907881 P3098 "NCT03598608" @default.
- Q61907881 P31 Q30612 @default.
- Q61907881 P4844 Q13896859 @default.
- Q61907881 P580 "2018-10-17T00:00:00Z" @default.
- Q61907881 P582 "2025-07-18T00:00:00Z" @default.
- Q61907881 P6099 Q42824440 @default.
- Q61907881 P6099 Q5452194 @default.
- Q61907881 P8363 Q78089383 @default.
- Q61907881 P859 Q58219685 @default.